ERBB2 and breast carcinoma: The FDA (Food and Drug Administration) has approved Olaparib and Talazoparib, and the NCCN (National Comprehensive Cancer Network) guidelines (Category 1) recommend them for treating HER2− advanced breast cancer with gBRCA1/2 mutations (Kang et al., 2025; Hennes et al., 2020).